Intraperitoneal drug delivery of antineoplastics (Q34315073)

1 August 2017

1 reference

title

Intraperitoneal drug delivery of antineoplastics (English)

1 reference

1 August 2017

1 reference

Markman M

1

1 reference

1 August 2017

1 January 2001

1 reference

1 August 2017

1 reference

1 August 2017

61

1 reference

1 August 2017

1057-1065

1 reference

1 August 2017

8

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200161080-00003

1 August 2017

0 references

cites work

Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study

1 reference

12 December 2020

Pentetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy

1 reference

12 December 2020

Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer

1 reference

12 December 2020

Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer

1 reference

12 December 2020

Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion

1 reference

12 December 2020

Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity

1 reference

12 December 2020

Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitro

1 reference

12 December 2020

Is there a role for intraperitoneal therapy in the management of gastrointestinal malignancies?

1 reference

12 December 2020

Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer

1 reference

12 December 2020

Pharmacokinetics of carboplatin after intraperitoneal administration

1 reference

12 December 2020

Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer

1 reference

12 December 2020

Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study

1 reference

12 December 2020

Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer

1 reference

12 December 2020

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

1 reference

12 December 2020

Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy

1 reference

12 December 2020

Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy

1 reference

12 December 2020

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer

1 reference

12 December 2020

1 reference

12 December 2020

Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy

1 reference

12 December 2020

Use of nitrogen mustard in treatment of serous effusions of neoplastic origin

1 reference

12 December 2020

Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma

1 reference

12 December 2020

Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure

1 reference

12 December 2020

Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group

1 reference

12 December 2020

Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study

1 reference

12 December 2020

Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study

1 reference

12 December 2020

Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: Lessons learned from a gynecologic oncology group phase II trial of ip cisplatin and recombinant α-interferon

1 reference

12 December 2020

Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer

1 reference

12 December 2020

Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy

1 reference

12 December 2020

Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route

1 reference

12 December 2020

Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma

1 reference

12 December 2020

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

12 December 2020

Peritoneal carcinomatosis from appendiceal cancer: results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy

1 reference

12 December 2020

Intraperitoneal chemotherapy

1 reference

12 December 2020

Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer

1 reference

12 December 2020

Intraperitoneal mitomycin C in the treatment of peritoneal carcinomatosis following second-look surgery

1 reference

12 December 2020

Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study

1 reference

12 December 2020

High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up

1 reference

12 December 2020

Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology

1 reference

12 December 2020

A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with Stage II-IV epithelial ovarian cancer following negative surgical assessment

1 reference

12 December 2020

Intraperitoneal cisplatin with systemic thiosulfate protection

1 reference

12 December 2020

Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin

1 reference

12 December 2020

Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer

1 reference

12 December 2020

In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration.

1 reference

12 December 2020

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

1 reference

12 December 2020

Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids.

1 reference

12 December 2020

Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer

1 reference

12 December 2020

10.2165/00003495-200161080-00003

Identifiers

DOI

1 reference

PubMed ID

11465869

Dimensions Publication ID

1 August 2017

0 references

1 reference

PubMed ID

11465869